Key secondary endpoints
skin lesion
SKIN LESION

Proportion of patients with improvement (reduction) in WI-NRS by ≥4 points from baseline to week 24 (PRIME2 only)Proportion of patients with reduction in skin lesion number to an IGA PN-S score of 0 or 1 at week 24 (PRIME and PRIME2)Proportion of patients concomitantly achieving a ≥4-point reduction in WI-NRS with an IGA PN-S of 0 or 1 at week 24 (PRIME and PRIME2, United States and United States-reference countries only)